AUTHOR INDEX

(P = Proceedings, S = Supplement)

AARONS, L. *see* SIMPSON, J.A.
ABDEL-RAHMAN, S.M. *see* DE WILDT, S.N.
ABRAMS, L.S., SKEE, D.M., NATARAJAN, J., WONG, F.A. & ANDERSON, G.D. Pharmacokinetics of a contraceptive patch (Evra™/Ortho Evra™) containing norelgestromin and ethinyloestradiol at four application sites., 141
ACKERMAN, E. *see* CROMHEECKE, H.
ACKERMAN, E. *see* VADER, C.
ADIGUN, A.Q. *see* AJAYI, A.A.L.
AFFOLTER, J.T., NEWBY, D.E. & WEBB, D.J. Vasomotor effects of arginne vasopressin in the human forearm circulation: the role of nitric oxide: 429P
AFFOLTER, J.T., WILKINSON, I.B., NEWBY, D.E. & WEBB, D.J. Systemic infusion of human urotensin II does not alter blood pressure or arterial stiffness: 428P
AHLNER;, J. *see* JOSEFSSON, M.
AHMED, M.S.-E. *see* HAMDY, S.I.
AIACH, M. *see* GAUSSEM, P.
AITHAL, G.P. *see* DALY, A.K.
AJAYI, A.A.L. & ADIGUN, A.Q. Syncope following oral chloroquine administration in a hypertensive patient controlled on amlodipine: 404
AL-EIDAN, F.A., MCELNAY, J.C., SCOTT, M.G. & MCCONNELL, J.B. Management of *Helicobacter pylori* eradication – the influence of structured counselling and follow-up: 163
ALEXEENKO, S. *see* FLEICHMAN, M.
ALLEN, M.J., OLIVER, S.D., NEWGREEN, M.W. & NICHOLS, D.J. Pharmacodynamic effect of continuous *vs* intermittent dosing of dofetilide on QT interval: 59
AL-RAWI, P.G. *see* HUTCHINSON, P.J.
AL-SHURBAJI, A. *see* BERTILSSON, L.
AMAKYE, D. *see* BRENNAN, N.
ANDERER, P. *see* RIBA, J.
ANDERSON, G.D. *see* ABRAMS, L.S.
ANDERSEN, G.N. *see* NYBERG, G.
ANDERSEN, M. *see* LARSEN, J.
ANGELO, H.R. *see* CHRISTOPHERSEN, A.B.
ANUMBA, D.O.C., ROBSON, S.C. & FORD, G.A. Flow-mediated nitric oxide activity in the forearm vasculature of premenopausal women: 332
ARAI, H. *see* TAGAWA, M.
ARMAND, J.P. *see* VAN KESTEREN, CH.
AUTRET-LECA, E. *see* JONVILLE-BÉRA, A.P.
AVILOVA, A. *see* FLEICHMAN, M.
AVOLIO, A.P. *see* McENIERY, C.M.

BABER, N.S. Review for Graduate Theraputics: A Primer for MRCP and Specialist Training: 215
BACK, D. *see* HENNESSY, M.
BACON, T.H., HOLE, J.G., NORTH, M. & BURNETT, I. Analgesic efficacy of sustained release paracetamol in patients with osteoarthritis of the knee: 629
BAIDOO, C. *see* KOCH, K.M.
BALDINI, E. *see* DANESI, R.
BALL, L. *see* CREMERS, S.
BARBANOJ, M.J. *see* RIBA, J.
BARRY, M. *see* HENNESSY, M.
BARTELINK, I. *see* THOMAS, H.D.
BATEMAN, D.N. *see* GOOD, A.M.
BATTY, K.T. *see* ILETT, K.F.
BEAU-SALINAS, F. *see* JONVILLE-BÉRA, A.P.
BECKWITH, S. *see* PENSON, R.T.
BEGG, E.J. *see* LENNARD, M.S.
BEIJNEN, J.H. *see* DE MAAT, M.M.R.
BEIJNEN, J.H. *see* STOKVIS, E.
BEIJNEN, J.H. *see* VAN DEN BONGARD, H.J.G.D.
BEIJNEN, J.H. *see* VAN HEESWIJK, R.P.G.
BEIJNEN, J.H. *see* VAN KESTEREN, CH.
BELLE, D.J., CALLAGHAN, J.T., GORSKI, J.C., MAYA, J.F., MOUSA, O., WRIGHTON, S.A. & HALL, S.D. The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activity: 67
BENGTSSON, F. *see* LUNDMARK, J.
BENNETT, K. *see* WILLIAMS, D.
BENNETT, P.N. *see* GORDON, J.N.
BERTILSSON, L., DAHL, M.-L., DALÉN, P. & AL-SHURBAJI, A. Molecular genetics of CYP2D6: Clinical relevance with focus on psychotropic drugs: 111
BERTRAND, G. *see* CHEVASSUS, H.
BINH, T.Q. *see* ILETT, K.F.
BISSLING, T.M., STEEGERS, E.A.P., WOUTERSE, A.C., ELVING, L., RUSSEL, F.G.M. & SMITS, P. Baseline function of placental vascular K_{ATP}-channels in healthy and in diabetic women, 548P
BJARNASON, I.T. *see* CHARLETT, A.
BJARNASON, K. *see* SKRUMSAGER, B.K.
BLACK, C., KAYE, J.A. & JICK, H. Clinical risk factors for venous thromboembolus in users of the combined oral contraceptive pill: 637
BLAIN, H., BOILEAU, C., LAPICQUE, F., NÉDÉLEC, E., LOEUILLE, D., GUILLAUME, C., GAUCHER, A., JEANDEL, C., NETTER, P. & JOUZEAU, J.-Y. Limitation of the *in vitro* whole blood assay for predicting the COX selectivity of NSAIDs in clinical use: 255
BLANC, P. *see* JONVILLE-BÉRA, A.P.
BLOT, W.J. *see* MELLEMKJÆR, L.
BLUM, R.A. *see* MAGEE, M.H.
BLUME, H.H. *see* SCHUG, B.S.
BOCCI, G. *see* DANESI, R.
BOCKAERT, J. *see* CHEVASSUS, H.
BODDY, A.V. *see* THOMAS, H.D.
BOILEAU, C. *see* BLAIN, H.
BOLSCHER, L. *see* LESLIE, S.J.
BONIFACE, S.J. *see* HUTCHINSON, P.J.
BOOLELL, M. *see* EARDLEY, I.
BORLEFFS, J.C.C. *see* VAN HEESWIJK, R.P.G.
BOS, L.P. *see* DERIJKS, L.J.J.
BOTMAN, C. *see* VADER, C.
BOWELL, A. *see* BOYCE, M.
BOYCE, M., BOWELL, A., CLARK, E.,DUNN, K., EVANS, A., JOHNSON, R., NORRIS, V. & WARRINGTON, S. Assessment by questionnaire of the process of informing study subjects: 436P
BOYCE, M., DUNN, K., LEWIS, Y., WICKS, J. & WARRINGTON, S. Potential impact of the European Clinical Trials Directive on UK phase I studies: 417P
BOYCE, M., WARRINGTON, S., LEWIS, Y., CATES, P. & HARRIS, A. Adaptation to the antisecretory effect of YF476, a new gastrin antagonist, in healthy men: 437P
BOYD, J.L. *see* DE HAAS, S.L.
BRADFORD, A.P.J. *see* WALTERS, M.R.
BRANCH, R.A. *see* FRYE, R.F.
BRAZELL, C., FREEMAN, A. & MOSTELLER, M. Maximizing the value of medicines by including pharmacogenetic research in drug development and surveillance: 224
BREDIUS, R. *see* CREMERS, S.
BREKELMANS, G.J. *see* KNOESTER, P.D.
BRENDEL, E. *see* SCHUG, B.S.
BRENNAN, N., CASE, N., MEYERS, T., AMAKYE, D., DOUGHTY, J., FORWARD, J.A., VARLEY, P., POWELL, J. & GLOVER, D.R. Pharmacokinetics of CAT-213, a human

© 2002 Blackwell Science Ltd

anti-eotaxin-1 monoclonal antibody, following single intravenous administration to healthy volunteers: 441P
BRICE, S. *see* O'RIORDAN, S.
BRINGER, J. *see* CHEVASSUS, H.
BRINKMANN, U. *see* DRESCHER, S.
BRITSCHGI, M. *see* NAISBITT, D.J.
BROUWERS, J.R.B.J. *see* FIJN, R.
BROUWERS, J.R.B.J. *see* FIJN, R.
BURGER, D.M. *see* VAN HEESWIJK, R.P.G.
BURHENNE, J. *see* MARTIN-FACKLAM, M.
BURKHART, C. *see* FARRELL, J.
BURNETT, I. *see* BACON, T.H.

CAIDAHL, K. *see* NYBERG, G.
CALLAGHAN, J.T. *see* BELLE, D.J.
CALLAGHAN, P.O. *see* HALL, M.
CALVERT, A.H. *see* THOMAS, H.D.
CALVO, R., LUKAS, J.C., RODRIGUEZ, M., CARLOS, M.A. & SUAREZ, E. Pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase efavirenz: 212
CAMPBELL, S. *see* CURNOW, A.
CAPPS, P.A.G. *see* JARERNSIRIPORNKUL, N.
CARLOS, M.A. *see* CALVO, R.
CASE, N. *see* BRENNAN, N.
CATES, P. *see* BOYCE, M.
CHADWICK, D.W. *see* NAISBITT, D.J.
CHANTRAINE, E. *see* SCHUG, B.S.
CHARLETT, A., OXLADE, N., DOBBS, R.J., DOBBS, S.M., WELLER, C., PETERSON, D.W. & BJARNASON, I.T. Rationale for eradication of *Helicobacter* in the cachexia of idiopathic parkinsonism: 448P
CHATFIELD, D.A. *see* HUTCHINSON, P.J.
CHESROWN, S. *see* TWISS, M.A.
CHEVASSUS, H., RENARD, E., BERTRAND, G., MOURAND, I., PUECH, R., MOLINIER, N., BOCKAERT, J., PETIT, P. & BRINGER, J. Effects of oral monosodium (L)-glutamate on insulin secretion and glucose tolerance in healthy volunteers: 641
CHEW, T.S. *see* SAVAGE, C.M.
CHO, J.-Y., YU, K.-S., JANG, I.-J., YANG, B.-H., SHIN, S.-G. & YIM, D.-S. Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19: 393
CHOW, M. *see* FIJN, R.
CHOWDRY, J. *see* ELLIS, S.W.
CHOWDRY, J., PUCCI, M.R., HARLOW, J., TUCKER, G.T. & ELLIS, S.W. Evidence that both phenylalanine 481 and phenylalanine 483 are substrate-contact residues in the active site of cytochrome P450 2D6: 443P
CHRISTIAANS, M.H.L. *see* STOLK, L.M.L.
CHRISTOPHERSEN, A.B., LEVIN, D., HOEGBERG, L.C.G., ANGELO, H.R. & KAMPMANN, J.P. Activated charcoal alone or after gastric lavage: a simulated large paracetamol intoxication: 312
CLARK, E. *see* BOYCE, M.
CLARKE, G.D. *see* SUTTON, J.A.
CLARKE, S.E. *see* KENNY, J.R.
CLOZEL, M. *see* DINGEMANSE, J.
COCKCROFT, J.R., HALL, I.R., MacCALLUM, H.I., MacKENZIE, S., McENIERY, C.M., WEBB, D.J. & WILKINSON, I.B. Assessment of endothelial function using pulse wave analysis: 413P
COCKCROFT, J.R. *see* McENIERY, C.M.
COCKCROFT, J.R. *see* WILKINSON, I.B.
COHEN STUART, J.W.T. *see* VAN HEESWIJK, R.P.G.
COLBURN, W. *see* MUIRHEAD, G.J.
COLE, M. *see* THOMAS, H.D.
COLEMAN, M.R. *see* HUTCHINSON, P.J.
COLES, J.P. *see* HUTCHINSON, P.J.
CONEMANS, J.M.H. *see* DE VRIES, E.M.
CONTE, P.F. *see* DANESI, R.
CRAWLEY, J. *see* OGUTU, B.R.
CREEMERS, J. *see* CROMHEECKE, H.
CREMERS, S., EEKHOFF, E., DAM, S.V., DEN HARTIGH, J., HAMDY, H., VERMEIJ, P. & PAPAPOULOS, S. Bisphosphonate (olpadronate) retention and its determinants in paget's disease of bone: 544P
CREMERS, S., SCHOEMAKER, R., BREDIUS, R., DEN HARTIGH, J., BALL, L., TWISS, I., VERMEIJ, P. & VOSSEN, J. Pharmacokinetics of intravenous busulfan in children prior to stem cell transplantation: 386
CROMHEECKE, H., GROULS, R., CREEMERS, J., SMEENK, F., VERBOOM, L. & ACKERMAN, E. Pharmacodynamic effects of albuterol nebulization in hospitalized COPD-patients because of an exacerbation with blocked gastrointestinal absorption: 556P
CUMMING, A.D. *see* GODDARD, J.
CURNOW, A., SALTER, L., MORLEY, N., CAMPBELL, S. & GOULD, D. Paracetamol can exacerbate irradiation-induced DNA damage: 338
DAHL, M.-L. *see* BERTILSSON, L.
DALÉN, P. *see* BERTILSSON, L.
DALHOFF, K. *see* SCHMIDT, L.E.
DALY, A.K., DAY, C.P. & AITHAL, G.P. CYP2C9 polymorphism and warfarin dose requirements: 408
DAM, S.V. *see* CREMERS, S.
DAMMER, S., NÜRNBERGER, J., MITCHELL, A., WENZEL, R.R., MICHEL, M.C., SIFFERT, W., PHILIPP, T. & SCHÄFERS, R.F. Evidence for a genetic determination of the response to clonidine in young, normotensive men carrying the 825T-allele of the G protein ß3 subunit gene: 422P
DANESI, R., INNOCENTI, F., FOGLI, S., GENNARI, A., BALDINI, E., DI PAOLO, A., SALVADORI, B., BOCCI, G., CONTE, P.F. & DEL TACCA, M. Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients: 508
DANHOF, M. *see* SWART, E.L.
DANJOU, P. *see* STONE, B.M.
DARWISH, M. *see* STONE, B.M.
DAVIE, A.P. & MCMURRAY, J.J.V. Effect of aspirin on vasodilation to bradykinin and substance P in patients with heart failure treated with ACE inhibitor: 37
DAVIS, T.M.E. *see* ILETT, K.F.
DAY, C.P. *see* DALY, A.K.
DE BLAEY, C.J. *see* FIJN, R.
DE BOER, A. *see* MANTEL-TEEUWISSE, A.K.
DE BOER, A. *see* VAN DE VIJVER, D.A.M.C.
DE BOER, ANTHONIUS *see* MAITLAND-VAN DER ZEE, ANKE-HILSE
DE BRUIN, M.L., VAN PUIJENBROEK, E.P., EGBERTS, A.C.G., HOES, A.W. & LEUFKENS, H.G.M. Non-sedating antihistamine drugs and cardiac arrhythmias – biased risk estimates from spontaneous reporting systems?: 370
DE HAAN, G.J. *see* KNOESTER, P.D.
DE HAAS, S.L., WILKINSON, I.B., BOYD, J.L. & WEBB, D.J. Local nitric oxide release does not affect tachyphlaxis to angiotensin II in dorsal hand veins in man in the presence of prostaglandin synthesis inhibition: 193
DE JONG, D.J. *see* DERIJKS, L.J.J.
DE JONG, P.E. *see* MONSTER, T.B.M.
DE JONG-VAN DEN BERG, L.T.W. *see* FIJN, R.
DE JONG-VAN DEN BERG, L.T.W*see* MONSTER, T.B.M.
DE LEIJ, LOU, F.M.H. *see* TAMMINGA, WIM J.

DE MAAT, M.M.R., HUITEMA, A.D.R., MULDER, J.W., MEENHORST, P.L., VAN GORP, E.C.M. & BEIJNEN, J.H. population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals: 552P
DE METZ, M. *see* VAN KRAAIJ, D.J.W.
DE NUCCI, G. *see* MORAES, L.A.
DE VRIES, E.M., POT, H.J., CONEMANS, J.M.H. & UGES, D.R.A. The clinical relevance of routine genotyping of CYP2D6/2C19 null of psychiatric patients: 550P
DE WILDT, S.N., KEARNS, G.L., HOP, W.C.J., MURRY, D.J., ABDEL-RAHMAN, S.M. & VAN DER ANKER, J.N. Pharmacokinetics and metabolism of oral midazolam in preterm infants: 390
DE ZEEUW, D. *see* WULFFELÉ, M.G.
DE ZEEUW, ROKUS A. *see* TAMMINGA, WIM J.
DEL TACCA, M. *see* DANESI, R.
DELESEN, H. *see* STASS, H.
DEN HARTIGH, J. *see* CREMERS, S.
DEN HARTIGH, J. *see* CREMERS, S.
DENVIR, M.A. *see* LESLIE, S.J.
DEPTA, J. *see* NAISBITT, D.J.
DERIJKS, L.J.J., DE JONG, D.J., GILISSEN, L.P.L., ENGELS, L.G.J.B., MULDER, C.J.J., BOS, L.P., LOHMAN, J.J.H.M. & HOOYMANS, P.M. 6-thioguanine in azathioprine and 6-mercaptopurine intolerant patients with inflammatory bowel disease: 546P
DI PAOLO, A. *see* DANESI, R.
DING, R. *see* MARTIN-FACKLAM, M.
DINGEMANSE, J., CLOZEL, M. & VAN GIERSBERGEN, P.L.M. Pharmacokinetics and pharmacodynamics of tezosentan, an intravenous dual endothelin receptor antagonist, following chronic infusion in healthy subjects: 355
DINGEMANSE, J., MEYERHOFF, C. & SCHADRACK, J. Effect of the catechol-O-methyltransferase inhibitor entacapone on the steady-state pharmacokinetics and pharmacodynamics of warfarin: 485
DINGEMANSE, J., SCHAARSCHMIDT, D. & VAN GIERSBERGEN, P.L.M. Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin: 547P
DINGEMANSE, J. *see* VAN GIERSBERGEN, P.L.M.
DITTRICH, CH. *see* VAN KESTEREN, CH.
DOBBS, R.J. *see* CHARLETT, A.
DOBBS, S.M. *see* CHARLETT, A.
DOGOLO, L. *see* JOSEFSSON, M.
DOUGHTY, J. *see* BRENNAN, N.
DRESCHER, S., SCHAEFFELER, E., HITZL, M., HOFMANN, U., SCHWAB, M., BRINKMANN, U., EICHELBAUM, M. & FROMM, M.F. *MDR1* gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine: 526
DROZ, J.P. *see* VAN KESTEREN, CH.
DUBAR, M. *see* GAUSSEM, P.
DUMEZ, H. *see* VAN KESTEREN, CH.
DUNCAN, J.S. Neurotransmitters, drugs and brain function: 648
DUNCAN, J.S. The promise of new antiepileptic drugs: 123
DUNN, K. *see* BOYCE, M.

EARDLEY, I., ELLIS, P., BOOLELL, M. & WULFF, M. Onset and duration of action of sildenafil for the treatment of erectile dysfunction: 61S
ECHIZEN, H. *see* SAIMA, S.
ECKHART, C. *see* GODDARD, J.
EDDERSHAW, P.J. *see* ELLIS, S.W.
EDELBROEK, P.M. *see* KNOESTER, P.D.
EDWARDS, G. & MUIRHEAD, G.J. Introduction to The Pharmacokinetics and Pharmacodynamics of Sildenafil Citrate Supplement: 1S
EDWARDS, G. *see* OGUTU, B.R.
EEKHOFF, E. *see* CREMERS, S.
EGBERTS, A.C.G. *see* DE BRUIN, M.L.
EGBERTS, A.C.G. *see* MOVIG, K.L.L.
EICHELBAUM, M. *see* DRESCHER, S.
EKINS-DAUKES, D.S., SIMPSON, C.R., TAYLOR, M.W., HELMS, P.J. & McLAY, J.S. Are asthmatic children at risk of exposure to a high corticosteroid burden in primary care?: 416P
EKINS-DAUKES, D.S., SIMPSON, C.R., TAYLOR, M.W., HELMS, P.J. & McLAY, I.S. Paediatric homeopathic prescribing in general practice: 433P
EL-ENANY, M. *see* HAMDY, S.I.
ELLIOTT, S. *see* THOMAS, H.D.
ELLIS, P. *see* EARDLEY, I.
ELLIS, S.W., KEENAN, L., HARLOW, J., CHOWDRY, J., GREGORY, A., MODI, S., EDDERSHAW, P.J. & TUCKER, G.T. Evidence that aspartic acid 301 and glutamic acid 216 are not alternative ligand-binding residues in the active site of cytochrome P450 2D6: 444P
ELLIS, S.W. *see* CHOWDRY, J.
ELVING, L. *see* BISSLING, T.M.
ENGELS, L.G.J.B. *see* DERIJKS, L.J.J.
EVANS, A. *see* BOYCE, M.

FARRELL, J., GORDON, S.F., NAISBITT, D.J., GALLIMORE, A., BURKHART, C., PICHLER, W.J., PIRMOHAMED, M. & PARK, B.K. MHC-restricted and processing dependent presentation of drug metabolite-modified cellular proteins to T-cells in the rat: 442P
FARRELL, J. *see* NAISBITT, D.J.
FAULKNER, S. *see* MUIRHEAD, G.J.
FAY, T.N. *see* STURROCK, N.D.C.
FEELY, J. *see* HENNESSY, M.
FEELY, J. *see* MAHMUD, A.
FEELY, J. *see* WILLIAMS, D.
FENECH, A. & HALL, I.P. Pharmacogenetics of asthma: 3
FERNER, R.E. *see* LANGFORD, N.J
FIJN, R., CHOW, M.C., SCHUUR, P.M.H., DE JONG-VAN DEN BERG, L.T.W. & BROUWERS, J.R.B.J. epidemiological evaluation of hospital prescribing concurrence with pharmacotherapeutic guidelines on infectious diseases, 559P
FIJN, R., VAN DEN BEMT, P.M.L.A., CHOW, M., DE BLAEY, C.J., DE JONG-VAN DEN BERG, L.T.W. & BROUWERS, J.R.B.J. Hospital prescribing errors: epidemiological assessment of predictors: 326
FISCHER, J. *see* WALTERS, M.R.
FISHER, G. *see* HUGHES, A.M.
FLEICHMAN, M., AVILOVA, A., JIVOTOVA, E., TIMOSHIN, S. & ALEXEENKO, S. Does angiotensin II affect cellular growth in gastric mucosa?: 447P
FOGLI, S. *see* DANESI, R.
FORD, G.A. *see* ANUMBA, D.O.C.
FORWARD, J.A. *see* BRENNAN, N.
FOULDS, G. *see* JOSEFSSON, M.
FOX, K.A.A*see* NEWBY, D.E.
FRANKLIN, S.S. *see* WILKINSON, I.B.
FRANSSEN, E.J.F., GREUTER, H.N.J.M., TOUW, D.J., LUURTSEMA, G., WINDHORST, A.D. & LAMMERTSMA, A.A. Plasma pharmacokinetics [C-11]flumazenil and its major metabolite [C-11] flumazenil 'acid': 554P
FREEMAN, A. *see* BRAZELL, C.
FRICKER, R. *see* MARTIN-FACKLAM, M.
FRIED, K.M. *see* YASUDA, S.U.
FRIEDMAN, H. *see* JOSEFSSON, M.
FROMM, M.F. *see* DRESCHER, S.
FROSSARD, N. *see* PUROHIT, A.
FRYE, R.F. & BRANCH, R.A. Effect of chronic disulfiram administration on the activities of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and N-acetyltransferase: 155
FUJII, T. *see* TAGAWA, M.
FUKUDA, J. *see* SAIMA, S.
FUMOLEAU, P. *see* VAN KESTEREN, CH.
FURLY, J. *see* HALL, M.
FURUIE, K. *see* SAIMA, S.

© 2002 Blackwell Science Ltd

GALLIMORE, A. *see* FARRELL, J.
GANSEVOORT, R.T. *see* WULFFELÉ, M.G.
GARNER, R., ROSTAMI-HODJEGAN, A., LENNARD, M.S., PRATT, P. & SEIVEWRIGHT, N. Views of the UK national guidelines on clinical management of drug misuse and dependence: a survey of methadone prescribers: 433P
GAUCHER, A. *see* BLAIN, H.
GAUSSEM, P., DUBAR, M., LE BONNIEC, B., RICHARD-LORDEREAU, I., JOCHEMSEN, R. & AIACH, M. Dose-effect relationship for several coagulation markers during adminstration of the direct thrombin inhibitor S 18326 in healthy subjects: 147
GENNARI, A. *see* DANESI, R.
GERRITS, M. *see* SKRUMSAGER, B.K.
GILISSEN, L.P.L. *see* DERIJKS, L.J.J.
GILLIN, W.P. *see* SUTTON, J.A.
GIRAUDEAU, B. *see* JONVILLE-BÉRA, A.P.
GLOVER, D.R. *see* BRENNAN, N.
GLOYNE, A. *see* PENSON, R.T.
GODDARD, J., ECKHART, C., CUMMING, A.D., RANKIN, A.J. & WEBB, D.J. Endothelin-A (ETA) receptor antagonism is synergistic with ACE inhibition in man via an ETB receptor mediated, nitric oxide (NO) dependent mechanism: 428P
GOEPEL, M. *see* SCHNEIDER, T.
GOEPEL, M. *see* MICHEL, M.C.
GOLDRING, C. *see* OWEN, A.
GOLDSCHMIDT, H.M.J. *see* MOVIG, K.L.L.
GOLDSTEIN, J.A. CYP2C9 polymorphisms and CYP2C9*2 genotyping primers: 410
GOOD, A.M., STRACHAN, F., OLIVER, J.J., KELLY, C.A. & BATEMAN, D.N. Licensing decisions and TOXBASE®–Evaluating the effect of restricted indications for thioridazine on its use in acute overdose: 416P
GOOD, A.M., STRACHAN, F., OLIVER, J.J., KELLY, C.A. & BATEMAN, D.N. The uses of an internet poisons information system for pharmacovigilance: case report analysis: 434P
GORDON, J.N., TAYLOR, A. & BENNETT, P.N. Lead poisoning: case studies: 451
GORDON, S.F. *see* FARRELL, J.
GORSKI, J.C. *see* BELLE, D.J.
GOULD, D. *see* CURNOW, A.
GRAATSMA, H.H. *see* VISSER, L.E.
GRAHAM, I. *see* HALL, M.
GRAM, L.F. *see* LARSEN, J.
GRATTAN, T.J. *see* SUTTON, J.A.
GREGORY, A. *see* ELLIS, S.W.
GREUTER, H.N.J.M. *see* FRANSSEN, E.J.F.
GROENEVELD, A.B.J. *see* SWART, E.L.
GROSSMAN, M. *see* LESLIE, S.J.
GROULS, R. *see* CROMHEECKE, H.
GROULS, R. *see* VADER, C.
GROWCOTT, J.W*see* HUGHES, A.M.
GUILLAUME, C. *see* BLAIN, H.
GUNNARSSON, T. *see* LUNDMARK, J.
GUPTA, A.K. *see* HUTCHINSON, P.J.

HACKETT, L.P. *see* ILETT, K.F.
HAEFELI, W.E. *see* MARTIN-FACKLAM, M.
HALABI, A. *see* STASS, H.
HALABI, A. *see* VAN GIERSBERGEN, P.L.M.
HALL, I.R. *see* COCKCROFT, J.R.
HALL, I.R. *see* WILKINSON, I.B.
HALL, I.P. *see* FENECH, A.
HALL, M., McGETTIGAN, M., CALLAGHAN, P.O., GRAHAM, I., SHELLEY, E. & FURLY, J. Management of cardiovascular risk factors in the 1990s – lifestyle worse, therapy better: 424P
HALL, S.D. *see* BELLE, D.J.
HAMDY, H. *see* CREMERS, S.
HAMDY, S.I., HIRATSUKA, M., NARAHARA, K., EL-ENANY, M., MOURSI, N., AHMED, M.S.-E. & MIZUGAKI, M. Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (*DPYD*) in the Egyptian population: 596
HARLOW, J. *see* CHOWDRY, J.
HARLOW, J. *see* ELLIS, S.W.
HARMAN, E. *see* TWISS, M.A.
HARNESS, J.A. *see* MUIRHEAD, G.J.
HARNESS, J.A. *see* NICHOLS, D.J.
HARNESS, J.A. *see* PURVIS, K.
HARRELL, A.W. *see* KENNY, J.R.
HARRIS, A. *see* BOYCE, M.
HARRIS, S. *see* JOSEFSSON, M.
HAUG-PIHALE, G. *see* MUIRHEAD, G.J.
HAYASHI, T. *see* SAIMA, S.
HEAZELL, M. *see* HUTCHINSON, P.J.
HEEREY, A. *see* WILLIAMS, D.
HEKSTER, Y.A. *see* VOGTLÄNDER, N.P.J.
HELFRICH, E., NEEF, C. & MERKUS, F.W.H.M. Population pharmacokinetics of intranasal administered low dose melatonin: 543P
HELMS, P.J. *see* EKINS-DAUKES, D.S.
HENDELES, L. *see* TWISS, M.A.
HENNESSY, M., KELLEHER, D., SPIERS, J.P., BARRY, M., KAVANAGH, P., BACK, D., MULCAHY, F. & FEELY, J. St John's Wort increases expression of P-glycoprotein: implications for Drug Interactions: 75
HIGHLEY, M. *see* THOMAS, H.D.
HIGUCHI, M. *see* TAGAWA, M.
HIRATSUKA, M. *see* HAMDY, S.I.
HITZL, M. *see* DRESCHER, S.
HODIAMONT, P.P.G. *see* MOVIG, K.L.L.
HOEGBERG, L.C.G. *see* CHRISTOPHERSEN, A.B.
HOES, A.W. *see* DE BRUIN, M.L.
HOETELMANS, R.M.W. *see* VAN HEESWIJK, R.P.G.
HOFFMANN, J.A. *see* MICHEL, M.C.
HOFMAN, ALBERT *see* MAITLAND-VAN DER ZEE, ANKE-HILSE
HOFMANN, U. *see* DRESCHER, S.
HOLE, J.G. *see* BACON, T.H.
HOOYMANS, P.M. *see* DERIJKS, L.J.J.
HOP, W.C.J. *see* DE WILDT, S.N.
HOVESTAD-WITTERLAND, A.H.I. *see* VAN KRAAIJ, D.J.W.
HUGHES, A.M., RHODES, J., FISHER, G., SELLERS, M. & GROWCOTT, J.W. Assessment of the effect of dextromethorphan and ketamine on the acute nociceptive threshold and wind-up of the second pain response in healthy male volunteers: 604
HUITEMA, A.D.R. *see* DE MAAT, M.M.R.
HULTSCH, E. *see* LESLIE, S.J.
HUNG, N.C. *see* ILETT, K.F.
HUTCHINSON, P.J., O'CONNELL, M.T., COLES, J.P., CHATFIELD, D.A., COLEMAN, M.R., AL-RAWI, P.G., KETT-WHITE, C.R., GUPTA, A.K., MENON, D.K., BONIFACE, S.J., HEAZELL, M., KIRKPATRICK, P.J. & PICKARD, J.D. Investigation of the effect of chlormethiazole on cerebral chemistry in neurosurgical patients: a combined study of microdialysis and a neuroprotective agent: 275
HUTCHINSON, M. *see* KAMALI, F.

ILETT, K.F., BATTY, K.T., POWELL, S.M., BINH, T.Q., THU, L.T.A., PHUONG, H.L., HUNG, N.C. & DAVIS, T.M.E. The pharmacokinetic properties of intramuscular artesunate and rectal dihydroartemisinin in uncomplicated falciparum malaria: 23
ILETT, K.F., KRISTENSEN, J.H., HACKETT, L.P., PAECH, M., KOHAN, R. & RAMPONO, J. Distribution of venlafaxine and its O-desmethyl metabolite in human milk and their effects in breastfed infants: 17
INNOCENTI, F. *see* DANESI, R.
ITOH, M. *see* TAGAWA, M.

JACKSON, P.R. *see* LEAMAN, H.
JACKSON, P.R. *see* MAJI, B.

JACKSON, S.H.D. *see* O'RIORDAN, S.
JAFFRAY, F. *see* KAMALI, F.
JANÉ, F. *see* RIBA, J.
JANG, I.-J. *see* CHO, J.-Y.
JANSEN, P.A.F. *see* SPAANS, E.
JANSEN, P.A.F. *see* VAN DE VIJVER, D.A.M.C.
JANSSEN, W.M.T. *see* MONSTER, T.B.M.
JARERNSIRIPORNKUL, N., KRSKA, J., CAPPS, P.A.G., RICHARDS, R.M.E. & LEE, A. Patient reporting of potential adverse drug reactions: a methodological study: 318
JEANDEL, C. *see* BLAIN, H.
JICK, H. *see* BLACK, C.
JICK, H. *see* YANG, C.-C.
JICK, S.S. *see* YANG, C.-C.
JIMENO, J.M. *see* STOKVIS, E.
JIVOTOVA, E. *see* FLEICHMAN, M.
JOCHEMSEN, R. *see* GAUSSEM, P.
JOEL, S.P. *see* PENSON, R.T.
JOHNSON, R. *see* BOYCE, M.
JOHNSON, T.N., ROSTAMI-HODJEGAN, A. & TUCKER, G.T. Oral midazolam for sedation in children: A pharmacokinetic-pharmacodynamic analysis: 437P
JONKER, D.M. *see* KNOESTER, P.D.
JONKMAN, JAN H.G. *see* TAMMINGA, WIM J.
JONVILLE-BÉRA, A.P., GIRAUDEAU, B., BLANC, P., BEAU-SALINAS, F. & AUTRET-LECA, E. Frequency of adverse drug reactions in children: A prospective study: 207
JOSEFSSON, M., AHLNER:, J., VINVENT, J., HARRIS, S., FOULDS, G., DOGOLO, L., WILLAVIZE, S. & FRIEDMAN, H. Amlodipine and grapefruit juice: 405
JOUZEAU, J.-Y. *see* BLAIN, H.
JUSKO, W.J*see* MAGEE, M.H.

KAMALI, F., JAFFRAY, F., KHAN, T., HUTCHINSON, M. & WYNNE, H. The impact of stability of oral anticoagulant therapy upon patient perceived health status and quality of life: 432P
KAMALI, F. *see* SICCARDI, D.
KAMPMANN, J.P. *see* CHRISTOPHERSEN, A.B.
KANO, M. *see* TAGAWA, M.
KARLSSON, M.O. *see* MILLIGAN, P.
KASTELEIN, JOHN J.P. *see* MAITLAND-VAN DER ZEE, ANKE-HILSE
KAVANAGH, P. *see* HENNESSY, M.
KAYE, J.A. *see* BLACK, C.
KEARNS, G.L. *see* DE WILDT, S.N.
KEENAN, L. *see* ELLIS, S.W.
KELLEHER, D. *see* HENNESSY, M.
KELLY, A. *see* WILLIAMS, D.
KELLY, C.A. *see* GOOD, A.M.
KENDALL, M.J. *see* LANGFORD, N.J
KENNY, J.R., HARRELL, A.W., CLARKE, S.E. & PARK, B.K. Metabolism and protein adduct formation from a carboxylic acid containing NSAID: 446P
KETT-WHITE, C.R. *see* HUTCHINSON, P.J.
KHAN, J. *see* LANGFORD, N.J
KHAN, T. *see* KAMALI, F.
KIEHR, B. *see* SKRUMSAGER, B.K.
KILMINSTER, S.G. *see* SUTTON, J.A.
KIRKPATRICK, P.J. *see* HUTCHINSON, P.J.
KLINTLAND, N. *see* NYBERG, G.
KLUNGEL, O.H. *see* MANTEL-TEEUWISSE, A.K.
KLUNGEL, OLAF H. *see* MAITLAND-VAN DER ZEE, ANKE-HILSE
KNOESTER, P.D., JONKER, D.M., VAN DER HOEVEN, R.T.M., VERMEIJ, T.A.C., EDELBROEK, P.M., BREKELMANS, G.J. & DE HAAN, G.J. Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray. A study in healthy volunteers: 501
KOCH, K.M., PALMER, J.L., NOORDIN, N., TOMLINSON, J.J. & BAIDOO, C. Sex and age differences in the pharmacokinetics of alosetron: 238
KOHAN, R. *see* ILETT, K.F.
KOKWARO, G.O. *see* OGUTU, B.R.
KOMEMUSHI, S. *see* TAGAWA, M.
KOOY, A. *see* WULFFELÉ, M.G.
KORSTEN, H. *see* VADER, C.
KRAGSTRUP, J. *see* LARSEN, J.
KREGE, S. *see* SCHNEIDER, T.
KRISTENSEN, J.H. *see* ILETT, K.F.
KRSKA, J. *see* JARERNSIRIPORNKUL, N.
KRUDSOOD, S. *see* LOOAREESUWAN, S.
KUBITZA, D. *see* STASS, H.
KULLBERG, B.J. *see* VOGTLÄNDER, N.P.J.

LABOY, L. *see* WILNER, K.
LAMMERTSMA, A.A. *see* FRANSSEN, E.J.F.
LANGFORD, N.J., KHAN, J., THORPE, G.H.G., NUTTALL, S., FERNER, R.E. & KENDALL, M.J. The effects of chronic paracetamol use on serum total antioxidant capacity in healthy volunteers: 446P
LANNON, B*see* STURROCK, N.D.C.
LAPICQUE, F. *see* BLAIN, H.
LARSEN, J., ANDERSEN, M., KRAGSTRUP, J. & GRAM, L.F. High persistence of statin use in a Danish population: Compliance study 1993–1998: 375
LATES, C.D. *see* MAGEE, M.H.
LE BONNIEC, B. *see* GAUSSEM, P.
LEAMAN, H. & JACKSON, P.R. What benefit do patients expect from adding second and third antihypertensive drugs?: 93
LEBEL, M. *see* WILNER, K.
LECKIE, S.M. *see* OLIVER, J.J.
LEE, A. *see* JARERNSIRIPORNKUL, N.
LEES, K.R. *see* WALTERS, M.R.
LENDERINK, A.W. *see* MOVIG, K.L.L.
LENNARD, M.S, RITTER, J.M., BEGG, E.J. & TUCKER, G.T. The Journal moves online for submission and peer review: 1
LENNARD, M.S. *see* GARNER, R.
LENNARD, L. *see* SAVAGE, C.M.
LENNARD, L. *see* WEBSTER, S.
LESLIE, S.J., HULTSCH, E., BOLSCHER, L., GROSSMAN, M., DENVIR, M. A. & WEBB, D.J. Comparison of two forearm plethysmography systems, *in vivo*, in man: Filtrass 2001 and Hokanson EC4: 426P
LESLIE, S.J., HULTSCH, E., BOLSCHER, L., GROSSMAN, M., DENVIR, M.A. & WEBB, D.J. The haemodynamic and neuroendocrine effects of systemic selective ET_A versus dual $ET_{A/B}$ antagonism in patients with chronic heart failure on standard therapy: 427P
LESLIE, S.J. *see* THOMSON, A.J.
LEUFKENS, H.G.M. *see* DE BRUIN, M.L.
LEUFKENS, H. *see* VADER, C.
LEUFKENS, H.G.M. *see* MOVIG, K.L.L.
LEUFKENS, HUBERTUS G.M. *see* MAITLAND-VAN DER ZEE, ANKE-HILSE
LEVIN, D. *see* CHRISTOPHERSEN, A.B.
LEWIS, P. Recombinant protein drugs: 412
LEWIS, Y. *see* BOYCE, M.
LILLEYMAN, J.S. *see* SAVAGE, C.M.
LOBO, A.J. *see* WEBSTER, S.
LOEUILLE, D. *see* BLAIN, H.
LOHMAN, J.J.H.M. *see* DERIJKS, L.J.J.
LONGMORE, J. *see* RAZZAQUE, Z.
LOOAREESUWAN, S., OOSTERHUIS, B., SCHILIZZI, B.M., SOLLIE, F.A.E., WILAIRATANA, P., KRUDSOOD, S., LUGT, CH.B., PEETERS, P.A.M. & PEGGINS, J.O. Dose-finding and efficacy study for i.m. artemotil (beta-arteether) and comparison with i.m. artemether in acute uncomplicated *P. falciparum* malaria: 492
LOONEN, A.J.M. *see* MOOKHOEK, J.M.
LÓPEZ-LÁZARO, L. *see* STOKVIS, E.
LUGT, CH.B. *see* LOOAREESUWAN, S.
LUKAS, J.C. *see* CALVO, R.
LUNDMARK, J., GUNNARSSON, T. & BENGTSSON, F. A possible interaction between lithium and rofecoxib: 403
LUURTSEMA, G. *see* FRANSSEN, E.J.F.

MA, Q.-P. *see* RAZZAQUE, Z.
MacCALLUM, H.I. *see* COCKCROFT, J.R.
MACCALLUM, H. *see* WILKINSON, I.B.
MacKENZIE, S. *see* COCKCROFT, J.R.
MAGEE, M.H., BLUM, R.A., LATES, C.D. & JUSKO, W.J. Pharmacokinetic/pharmacodynamic model for prednisolone inhibition of whole blood lymphocyte proliferation: 474
MAHMUD, A. & FEELY, J. Angiotensin II antagonism – a blood pressure-independent effect on arterial stiffness in essential hypertension?: 421P
MAHMUD, A. & FEELY, J. Chronic alcohol excess in men is associated with arterial stiffening and raises aortic systolic blood pressure: 421P
MAITLAND-VAN DER ZEE, ANKE-HILSE, STRICKER, BRUNO, H. CH., KLUNGEL, OLAF, H., KASTELEIN, JOHN, J.P., HOFMAN, ALBERT, LEUFKENS, HUBERTUS G.M., VAN BROECKHOVEN, CHRISTINE, VAN DUIJN, CORNELIA, M. & DE BOER, ANTHONIUS. The effectiveness of hmg-coa reductase inhibitors in an elderly population is independent of apolipoprotein e-genotypes: 548P
MAJI, B. & JACKSON, P.R. Patients' preference for treatments offering greater relative benefit: 435P
MANDAJIEVA, M. *see* TZACHEV, C.T.
MANTEL-TEEUWISSE, A.K., KLUNGEL, O.H., VERSCHUREN, W.M.M., PORSIUS, A.J. & DE BOER, A. Time trends in lipid lowering drug use in The Netherlands. Has the backlog of candidates for treatment been eliminated?: 379
MANTEL-TEEUWISSE, A.K., VERSCHUREN, W.M.M., KLUNGEL, O.H., PORSIUS, A.J. & DE BOER, A. Determinants of undertreatment of hypercholesterolaemia in a population-based study in the Netherlands: 557P
MARRIOTT, J.F. *see* WHITFIELD, K.M.
MARSH, K. *see* OGUTU, B.R.
MARSHALL, S.F. *see* MILLIGAN, P.
MARTIN, W. *see* SCHUG, B.S.
MARTIN-FACKLAM, M., BURHENNE, J., DING, R., FRICKER, R., MIKUS, G., WALTER-SACK, I. & HAEFELI, W.E. Dose-dependent increase of saquinavir bioavailability by the pharmaceutic aid cremophor EL.: 576
MATHÔT, R.A.A. *see* VAN DEN BONGARD, H.J.G.D.
MATHÔT, R.A.A. *see* VAN KESTEREN, CH.
MATSUDA, M. *see* TAGAWA, M.
MAXWELL, S.R.J. *see* THOMSON, A.J.
MAYA, J.F. *see* BELLE, D.J.
McCONNELL, J.B. *see* AL-EIDAN, F.A.
McCORMICK, J. Recreational bupropion abuse in a teenager: 214
McELNAY, J.C. *see* AL-EIDAN, F.A.
McENIERY, C.M., WILKINSON, I.B., QASEM, A., AVOLIO, A.P., WEBB, D.J. & COCKCROFT, J.R. Nitric oxide regulates large artery stiffness *in vivo*: 426P
McENIERY, C.M. *see* COCKCROFT, J.R.
McGETTIGAN, M. *see* HALL, M.
McINTYRE, C. Prescribing statins for primary prevention of coronary heart disease based on modifiable risk: 423P
McLAUGHLIN, J.K. *see* MELLEMKJÆR, L.
McLAY, I.S. *see* EKINS-DAUKES, D.S.
McLAY, J.S. *see* EKINS-DAUKES, D.S.
McMURRAY, J.J.V. *see* DAVIE, A.P.
MEENHORST, P.L. *see* DE MAAT, M.M.R.
MÉLAC, M. *see* PUROHIT, A.
MELLEMKJÆR, L., BLOT, W.J., SORENSEN, H.T., THOMASSEN, L., MCLAUGHLIN, J.K., NIELSEN, G.L. & OLSEN, J.H. Upper gastrointestinal bleeding among users of NSAIDs: a population-based cohort study in Denmark: 173
MELLEMKJAER, L. *see* TERAO, T.
MELVILLE, V. *see* OLIVER, J.J.
MENON, D.K. *see* HUTCHINSON, P.J.
MERKUS, F.W.H.M. *see* HELFRICH, E.
MEYERHOFF, C. *see* DINGEMANSE, J.
MEYERS, T. *see* BRENNAN, N.
MICHEL, M.C., HOFFMANN, J.A., PIRO, M., RÜBBEN, H. & GOEPEL, M. Prevalence and physician awareness of symptoms of bladder dysfunction: 435P
MICHEL, M.C. *see* DAMMER, S.
MICHEL, M.C. *see* SCHNEIDER, T.
MIKUS, G. *see* MARTIN-FACKLAM, M.
MILLIGAN, P., MARSHALL, S.F. & KARLSSON, M.O. A population pharmacokinetic analysis of sildenafil citrate in patients with erectile dysfunction: 45S
MILLS, S.L. *see* STONE, B.M.
MINKOV, E.H. *see* TZACHEV, C.T.
MITCHELL, A. *see* DAMMER, S.
MIZUGAKI, M. *see* HAMDY, S.I.
MIZUKI, Y. *see* TAGAWA, M.
MODI, S. *see* ELLIS, S.W.
MOLINIER, N. *see* CHEVASSUS, H.
MONSTER, T.B.M., JANSSEN, W.M.T., DE JONG, P.E. & DE JONG-VAN DEN BERG, L.T.W. The impact of antihypertensive drug groups on urinary albumin excretion in a non-diabetic population: 31
MOOKHOEK, E.J. & LOONEN, A.J.M. Does the change of omeprazole to pantoprazole affect clozapine plasma concentrations?: 545P
MORAES, L.A., RIBEIRO, W. & DE NUCCI G. Pharmacokinetics of RSD921, a new sodium channel blocking agent: a phase I study: 440P
MORGAN, P. *see* OWEN, A.
MORICE, A.H. Muscarinic receptors in airways diseases: 215
MORLEY, N. *see* CURNOW, A.
MORRISON, K. *see* RAZZAQUE, Z.
MORTE, A. *see* RIBA, J.
MOSTELLER, M. *see* BRAZELL, C.
MOURAND, I. *see* CHEVASSUS, H.
MOURSI, N. *see* HAMDY, S.I.
MOUSA, O. *see* BELLE, D.J.
MOVIG, K.L.L., LEUFKENS, H.G.M., LENDERINK, A.W., VAN DEN AKKER, V.G.A., HODIAMONT, P.P.G., GOLDSCHMIDT, H.M.J. & EGBERTS, A.C.G. Association between antidepressant drug use and hyponatraemia: a case-control study: 363
MUCHOHI, S.N. *see* OGUTU, B.R.
MUCKLOW, J.C. What knowledge and skills are essential for specialists in Clinical Pharmacology and Therapeutics? Results of a Delphi study: 341
MUIRHEAD, G.J., FAULKNER, S., HARNESS, J.A. & TAUBEL, J. The effects of steady-state erythromycin and azithromycin on the pharmacokinetics of sildenafil in healthy volunteers: 37S
MUIRHEAD, G.J., RANCE, D.J., WALKER, D.K. & WASTALL, P. Comparative human pharmacokinetics and metabolism of single-dose oral and intravenous sildenafil: 13S
MUIRHEAD, G.J., WILNER, K., COLBURN, W., HAUG-PIHALE, G. & ROUVIEX, B. The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil: 21S
MUIRHEAD, G.J. *see* EDWARDS, G.
MUIRHEAD, G.J. *see* NICHOLS, D.J.
MUIRHEAD, G.J. *see* PURVIS, K.
MULCAHY, F. *see* HENNESSY, M.
MULDER, C.J.J. *see* DERIJKS, L.J.J.
MULDER, J.W. *see* DE MAAT, M.M.R.
MURRY, D.J. *see* DE WILDT, S.N.

NAISBITT, D.J., BRITSCHGI, M., WONG, G., FARRELL, J., CHADWICK, D.W., PICHLER, W.J., PIRMOHAMED, M. & PARK, B.K. Anticonvulsant hypersensitivity syndrome: characterisation of the phenotype and cytokine profile of carabamazepine-specific T-cell clones: 418P

NAISBITT, D.J., DEPTA, J., WONG, G., FARRELL, J., CHADWICK, D.W., PICHLER, W.J., PIRMOHAMED, M. & PARK, B.K. Anticonvulsant hypersensitivity syndrome: Methodology to investigate the role of metabolism and processing of carbamazepine to T-cells: 443P
NAISBITT, D.J. *see* FARRELL, J.
NARAHARA, K. *see* HAMDY, S.I.
NATARAJAN, J. *see* ABRAMS, L.S.
NATSCH, S. *see* VOGTLÄNDER, N.P.J.
NÉDÉLEC, E. *see* BLAIN, H.
NEEF, C. *see* HELFRICH, E.
NETTER, P. *see* BLAIN, H.
NEWBY, D.E. & FOX, K.A.A. Invasive assessment of the coronary circulation: intravascular ultrasound and Doppler: 561
NEWBY, D.E. *see* AFFOLTER, J.T.
NEWELL, D.R. *see* THOMAS, H.D.
NEWGREEN, M.W. *see* ALLEN, M.J.
NEWTON, C.R.J.C. *see* OGUTU, B.R.
NGUYEN, L., TRANCHAND, B., PUOZZO, C. & VARIOL, P. Population pharmacokinetics model and limited sampling strategy for intravenous vinorelbine derived from phase I clinical trials: 459
NICHOLS, D.J., MUIRHEAD, G.J. & HARNESS, J.A. Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality: 5S
NICHOLS, D.J. *see* ALLEN, M.J.
NIELSEN, G.L. *see* MELLEMKJÆR, L.
NOBBS, J.R. *see* THOMAS, H.D.
NOORDIN, N. *see* KOCH, K.M.
NORRIS, V. *see* BOYCE, M.
NORTH, M. *see* BACON, T.H.
NÜRNBERGER, J. *see* DAMMER, S.
NUTTALL, S. *see* LANGFORD, N.J
NYBERG, G., ANDERSEN, G.N., RANTAPÄÄ-DAHLQUIST, S., KLINTLAND, N. & CAIDAHL, K. Pulse wave tonometry in patients with systemic sclerosis and healthy controls: effects of nitroglycerin and methodological considerations: 414P

O'CONNELL, M.T. *see* HUTCHINSON, P.J.
O'DONNELL, C., WILLIAMS, D.P., PIRMOHAMED, M., UETRECHT, J.P. & PARK, B.K. Clozapine metabolism and redox regulation of transcription factors in human neutrophils: 419P
O'RIORDAN, S., OULDRED, E., BRICE, S., JACKSON, S.H.D. & SWIFT, C.G. Serum cystatin C is not a better marker of creatinine or digoxin clearance than serum creatinine: 398
OGUTU, B.R., NEWTON, C.R.J.C., CRAWLEY, J., MUCHOHI, S.N., OTIENO, G.O., EDWARDS, G., MARSH, K. & KOKWARO, G.O. Pharmacokinetics and anticonvulsant effects of diazepam in children with severe falciparum malaria and convulsions: 49
OKAMURA, N. *see* TAGAWA, M.
OLIVER, J.J., WILKINSON, I.B.W., STRACHAN, F.E., LECKIE, S.M., MELVILLE, V. & WEBB, D.J. A single-blind study to characterise the development of nitrate tolerance following administration of 10 mg transdermal GTN in healthy volunteers *in vivo*: 414P
OLIVER, S.D. *see* ALLEN, M.J.
OLIVER, J.J. *see* GOOD, A.M.
OLSEN, J.H. *see* MELLEMKJÆR, L.
OLSEN, J.H. *see* TERAO, T.
OOSTERHUIS, B. *see* LOOAREESUWAN, S.
OOSTERHUIS, BEREND*see* TAMMINGA, WIM J.
OSTERLOH, I.H. & RILEY, A. Clinical update on sildenafil citrate: 219
OTIENO, G.O. *see* OGUTU, B.R.
OULDRED, E. *see* O'RIORDAN, S.
OWEN, A., GOLDRING, C.,MORGAN, P., PARK, B.K. & PIRMOHAMED M. Absence of correlation between $C_{3435}T$ polymorphism in the *MDR1* gene and expression of P-glycoprotein in human liver: 420P
OXLADE, N. *see* CHARLETT, A.

PAECH, M. *see* ILETT, K.F.
PALMER, J.L. *see* KOCH, K.M.
PARK, B.K. *see* FARRELL, J.
PARK, B.K. *see* KENNY, J.R.
PARK, B.K. *see* NAISBITT, D.J.
PARK, B.K. *see* O'DONNELL, C.
PARK, B.K. *see* OWEN, A.
PATAT, A. *see* STONE, B.M.
PATY, I. *see* STONE, B.M.
PAULI, G. *see* PUROHIT, A.
PEDERSEN, P.C. *see* SKRUMSAGER, B.K.
PEETERS, P.A.M. *see* LOOAREESUWAN, S.
PEGGINS, J.O. *see* LOOAREESUWAN, S.
PENSON, R.T., JOEL, S.P., ROBERTS, M., GLOYNE, A., BECKWITH, S. & SLEVIN, M.L. The bioavailability and pharmacokinetics of subcutaneous, nebulized and oral morphine-6-glucuronide: 347
PETERSON, D.W. *see* CHARLETT, A.
PETIT, P. *see* CHEVASSUS, H.
PHILIPP, T. *see* DAMMER, S.
PHUONG, H.L. *see* ILETT, K.F.
PICHLER, W.J. *see* FARRELL, J.
PICHLER, W.J. *see* NAISBITT, D.J.
PICKARD, J.D. *see* HUTCHINSON, P.J.
PICKARD, J.D. *see* RAZZAQUE, Z.
PIRMOHAMED, M. *see* FARRELL, J.
PIRMOHAMED, M. *see* NAISBITT, D.J.
PIRMOHAMED, M. *see* O'DONNELL, C.
PIRMOHAMED, M. *see* OWEN, A.
PIRO, M. *see* MICHEL, M.C.
POPOV, T.A. *see* TZACHEV, C.T.
PORSIUS, A.J. *see* MANTEL-TEEUWISSE, A.K.
PORSIUS, A.J. *see* VAN DE VIJVER, D.A.M.C.
PORTER, D.J. *see* THOMAS, H.D.
POT, H.J. *see* DE VRIES, E.M.
POWELL, J. *see* BRENNAN, N.
POWELL, S.M. *see* ILETT, K.F.
PRATT, P. *see* GARNER, R.
PRICE, R. *see* SIMPSON, J.A.
PUCCI, M.R. *see* CHOWDRY, J.
PUECH, R. *see* CHEVASSUS, H.
PUNT, C. *see* VAN KESTEREN, CH.
PUOZZO, C. *see* NGUYEN, L.
PUROHIT, A., MÉLAC, M., PAULI, G. & FROSSARD, N. Comparative activity of cetirizine and mizolastine on histamine-induced skin wheal and flare responses at 24 hours: 250
PURVIS, K., MUIRHEAD, G.J. & HARNESS, J.A. The effects of sildenafil on human sperm function in healthy volunteers: 53S

QASEM, A. *see* McENIERY, C.M.

RAFTERY, A.T. Modern immunosuppressives: 216
RALSTON, C. *see* WHITFIELD, K.M.
RAMPONO, J. *see* ILETT, K.F.
RANKIN, A.J. *see* GODDARD, J.
RANTAPÄÄ-DAHLQUIST, S. *see* NYBERG, G.
RAVIC, M. *see* VAN KESTEREN, CH.
RAWLINSON, W. Antiviral agents: advances and problems: 542
RAYMOND, E. *see* VAN KESTEREN, CH.
RAZZAQUE, Z., PICKARD, J.D., MA, Q.-P., SHAW, D., MORRISON, K., WANG, T. & LONGMORE, J. HT_{1B}-receptors and vascular reactivity in human isolated blood vessels: assessment of the potential craniovascular selectivity of sumatriptan: 266
RENARD, E. *see* CHEVASSUS, H.
RHODES, J. *see* HUGHES, A.M.
RIBA, J., ANDERER, P., MORTE, A., URBANO, G., JANÉ, F., SALETU, B. & BARBANOJ, M.J. Topographic pharmaco-EEG mapping of the effects of the South American psychoactive beverage *Ayahuasca* in healthy volunteers: 613

RIBEIRO, W. *see* MORAES, L.A.
RICHARD-LORDEREAU, I. *see* GAUSSEM, P.
RICHARDS, R.M.E. *see* JARERNSIRIPORNKUL, N.
RILEY, A. *see* OSTERLOH, I.H.
RITTER, J.M. *see* LENNARD, M.S.
ROBERTS, M. *see* PENSON, R.T.
ROBSON, S.C. *see* ANUMBA, D.O.C.
ROCHÉ, H. *see* VAN KESTEREN, CH.
RODRIGUEZ, M. *see* CALVO, R.
RONGEN, G.A. *see* VERKAIK, N.J.
ROOS, R.A.C. *see* VAN DE VIJVER, D.A.M.C.
ROSING, H. *see* STOKVIS, E.
ROSTAMI-HODJEGAN, A. *see* GARNER, R.
ROSTAMI-HODJEGAN, A. *see* JOHNSON, T.N.
ROSTAMI-HODJEGAN, A. *see* YANG, J.S.
ROUVIEX, B. *see* MUIRHEAD, G.J.
ROWLAND YEO, K. & YEO, W.W. Antihypertensive treatment and blood pressure control: the health survey for England 1998: 424P
RÜBBEN, H. *see* MICHEL, M.C.
RUSSEL, F.G.M. *see* BISSLING, T.M.

SAIMA, S., FURUIE, K., YOSHIMOTO, H., FUKUDA, J., HAYASHI, T. & ECHIZEN, H. The effects of rifampicin on the pharmacokinetics and pharmacodynamics of orally administered nilvadipine to healthy subjects: 203
SALETU, B. *see* RIBA, J.
SALTER, L. *see* CURNOW, A.
SALVADORI, B. *see* DANESI, R.
SANDERS, D.S. *see* WEBSTER, S.
SASAKI, H. *see* TAGAWA, M.
SAVAGE, C.M., CHEW, T.S., LILLEYMAN, J.S. & LENNARD, L. Thiopurine methyltransferase in childhood leukaemia: variation in enzyme activity at disease diagnosis and during chemotherapy: 439P
SCHAARSCHMIDT, D. *see* DINGEMANSE, J.
SCHADRACK, J. *see* DINGEMANSE, J.
SCHAEFFELER, E*see* DRESCHER, S.
SCHÄFERS, R.F. *see* DAMMER, S.
SCHALL, R. *see* SCHUG, B.S.
SCHELLENS, J.H.M. *see* STOKVIS, E.
SCHELLENS, J.H.M. *see* VAN DEN BONGARD, H.J.G.D.
SCHELLENS, J.H.M. *see* VAN KESTEREN, CH.
SCHILIZZI, B.M. *see* LOOAREESUWAN, S.
SCHMIDT, L.E. & DALHOFF, K. Concomitant overdosing of other drugs in patients with paracetamol poisoning: 535
SCHNEIDER, T., KREGE, S., GOEPEL, M. & MICHEL, M.C. Do age or gender affect the efficacy or tolerability of tolterodine?: 418P
SCHOEMAKER, R. *see* CREMERS, S.
SCHÖNBERGER, J. *see* VADER, C.
SCHUG, B.S., BRENDEL, E., CHANTRAINE, E., WOLF, D., MARTIN, W., SCHALL, R. & BLUME, H.H. The effect of food on the pharmacokinetics of nifedipine in two slow release formulations: pronounced lag-time after a high fat breakfast: 582
SCHUUR, P.M.H. *see* FIJN, R.
SCHWAB, M. *see* DRESCHER, S.
SCOTT, M.G. *see* AL-EIDAN, F.A.
SEIVEWRIGHT, N. *see* GARNER, R.
SELLERS, M. *see* HUGHES, A.M.
SHAW, D. *see* RAZZAQUE, Z.
SHELLEY, E. *see* HALL, M.
SHIN, S.-G. *see* CHO, J.-Y.
SICCARDI, D. & KAMALI, F. Stereoselectivity in thioridazine metabolism *in vitro*: 445P
SIFFERT, W. *see* DAMMER, S.
SIMPSON, J.A., AARONS, L., PRICE, R. & WHITE, N.J. The influence of body weight on the pharmacokinetics of mefloquine: 337
SIMPSON, C.R. *see* EKINS-DAUKES, D.S.
SKEE, D.M. *see* ABRAMS, L.S.
SKRUMSAGER, B.K., KIEHR, B., PEDERSEN, P.C., GERRITS, M., WATSON, N. & BJARNASON, K. Levormeloxifene: safety, pharmacodynamics and pharmacokinetics in healthy postmenopausal women following single and multiple does of a new selective oestrogen receptor modulator: 284
SLEVIN, M.L. *see* PENSON, R.T.
SMEENK, F. *see* CROMHEECKE, H.
SMITS, P. *see* BISSLING, T.M.
SMITS, P. *see* VERKAIK, N.J.
SOLLIE, F.A.E. *see* LOOAREESUWAN, S.
SORENSEN, H.T. *see* MELLEMKJÆR, L.
SORENSEN, H.T. *see* TERAO, T.
SPAANS, E. & JANSEN, P.A.F. Evaluation of the use of a medication database as a tool for detecting drug interactions: 558P
SPIERS, J.P. *see* HENNESSY, M.
STASS, H., KUBITZA, D., HALABI, A. & DELESEN, H. Pharmacokinetics of moxifloxacin, a novel 8-methoxy-quinolone, in patients with renal dysfunction: 232
STEEGERS, E.A.P. *see* BISSLING, T.M.
STEHOUWER, C.D.A. *see* WULFFELÉ, M.G.
STOKVIS, E., ROSING, H., LÓPEZ-LÁZARO, L., JIMENO, J.M., SUPKO, J.G., SCHELLENS, J.H.M. & BEIJNEN, J.H. Bioanalysis of the novel peptide anticancer drug kahalalide F in human plasma by h.p.l.c under basic conditions coupled with positive turbo-ionspray tandem mass spectrometry: 543P
STOLK, L.M.L., VAN DUIJNHOVEN, E.M., CHRISTIAANS, M.H.L. & VAN HOOFF, J.P. Evaluation of prediction of tacrolimus area under the curve by trough concentrations: 554P
STONE, B.M., TURNER, C., MILLS, S.L., PATY, I., PATAT, A., DARWISH, M. & DANJOU, P. Noise-induced sleep maintenance insomnia: hypnotic and residual effects of zaleplon: 196
STRACHAN, F. *see* GOOD, A.M.
STRACHAN, F.E. *see* OLIVER, J.J.
STRICKER, B.H.CH. *see* VISSER, L.E.
STRICKER, BRUNO H.CH. *see* MAITLAND-VAN DER ZEE, ANKE-HILSE
STURROCK, N.D.C., LANNON, B & FAY, T.N. Metformin does not enhance ovulation induction in clomiphene resistant polysystic ovary syndrome in clinical practice: 469
SUAREZ, E. *see* CALVO, R.
SUPKO, J.G. *see* STOKVIS, E.
SUTTON, J.A., GILLIN, W.P., GRATTAN, T.J., CLARKE, G.D. & KILMINSTER, S.G. A new laser pain threshold model detects a faster onset of action from a liquid formulation of 1 g paracetamol than an equivalent tablet formulation: 43
SWART, E.L., VAN DER HOVEN, B., GROENEVELD, A.B.J., TOUW, D.J. & DANHOF, M. Correlation between midazolam and lignocaine pharmacokinetics and MEGX formation in healthy volunteers: 133
SWIFT, C.G. *see* O'RIORDAN, S.

TAGAWA, M., KANO, M., OKAMURA, N., HIGUCHI, M., MATSUDA, M., MIZUKI, Y., ARAI, H., FUJII, T., KOMEMUSHI, S., ITOH, M., SASAKI, H., WATANABE, T. & YANAI, K. Differential cognitive effects of ebastine and (+)-chlorpheniramine in healthy subjects: Correlation between cognitive impairment and plasma drug concentration: 296
TAMMINGA, WIM J., WEMER, JOHAN, OOSTERHUIS, BEREND, DE ZEEUW, ROKUS A., DE LEIJ, LOU F.M.H. & JONKMAN, JAN H.G. The prevalence of cyp2c19 genotypes in a population of healthy dutch volunteers and apparent gender differences in phenotypes: 550P

TAUBEL, J. *see* MUIRHEAD, G.J.
TAYLOR, A. *see* GORDON, J.N.
TAYLOR, M.W. *see* EKINS-DAUKES, D.S.
TELJEUR, C. *see* WILLIAMS, D.
TER WOORST, F. *see* VADER, C.
TERAO, T., SORENSEN, H.T., MELLEMKJAER, L. & OLSEN, J.H. β-adrenoceptor blockers and serotonin: 407
THOMAS, H.D., PORTER, D.J., BARTELINK, I., NOBBS, J.R., COLE, M., ELLIOTT, S., NEWELL, D.R., CALVERT, A.H., HIGHLEY, M. & BODDY, A.V. Randomized cross-over clinical trial to study potential pharmacokinetic interactions between cisplatin or carboplatin and etoposide: 83
THOMASSEN, L. *see* MELLEMKJÆR, L.
THOMSON, A.J., LESLIE, S.J.,MAXWELL, S.R.J. & WEBB, D.J. A comparison between two thoracic electrical bioimpedance monitors – BoMed® NCCOM3-R7 and EXTTEBCO® (with Hotman®F100 software): 430P
THORPE, G.H.G. *see* LANGFORD, N.J
THU, L.T.A. *see* ILETT, K.F.
TIMOSHIN, S. *see* FLEICHMAN, M.
TOMLINSON, J.J. *see* KOCH, K.M.
TOUW, D.J. *see* FRANSSEN, E.J.F.
TOUW, D.J. *see* SWART, E.L.
TRANCHAND, B. *see* NGUYEN, L.
TUCKER, G.T. *see* CHOWDRY, J.
TUCKER, G.T. *see* ELLIS, S.W.
TUCKER, G.T. *see* JOHNSON, T.N.
TUCKER, G.T. *see* LENNARD, M.S.
TUCKER, G.T. *see* YANG, J.S.
TURNER, C. *see* STONE, B.M.
TWISS, I. *see* CREMERS, S.
TWISS, M.A., HARMAN, E., CHESROWN, S. & HENDELES, L. Efficacy of calcium channel blockers as maintenance therapy for asthma: 243
TYRRELL, S. *see* WILKINSON, I.B.
TZACHEV, C.T., MANDAJIEVA, M., MINKOV, E.H. & POPOV, T.A. Comparison of the clinical efficacy of standard and mucoadhesive-based nasal decongestants: 107

UETRECHT, J.P. *see* O'DONNELL, C.
UGES, D.R.A. *see* DE VRIES, E.M.
URBANO, G. *see* RIBA, J.

VADER, C., GROULS, R., VAN GERVEN, A., ACKERMAN, E., KORSTEN, H., SCHÖNBERGER, J., TER WOORST, F., BOTMAN, C. & LEUFKENS, H. Interaction between sotalol and albuterol after CABG: influence on postoperative arrhythmias and length of stay at an intensive care unit, 555P
VAN BROECKHOVEN, CHRISTINE *see* MAITLAND-VAN DER ZEE, ANKE-HILSE
VAN DE VIJVER, D.A.M.C., ROOS, R.A.C., JANSEN, P.A.F., PORSIUS, A.J. & DE BOER, A. use of antipsychotics in Parkinson's disease in daily practice: 551P
VAN DEN AKKER, V.G.A. *see* MOVIG, K.L.L.
VAN DEN BEMT, P.M.L.A. *see* FIJN, R.
VAN DEN BONGARD, H.J.G.D., MATHÔT, R.A.A., VAN TELLINGEN, O., SCHELLENS, J.H.M. & BEIJNEN, J.H. A population pharmacokinetic model for cremophor EL using nonlinear mixed-effect modeling: model building and validation, 552P
VAN DER ANKER, J.N. *see* DE WILDT, S.N.
VAN DER HOEVEN, R.T.M. *see* KNOESTER, P.D.
VAN DER HOVEN, B. *see* SWART, E.L.
VAN DER MEER, J.W.M. *see* VOGTLÄNDER, N.P.J.
VAN DUIJN, CORNELIA *see* MAITLAND-VAN DER ZEE, ANKE-HILSE
VAN DUIJNHOVEN, E.M. *see* STOLK, L.M.L.
VAN GERVEN, A. *see* VADER, C.
VAN GIERSBERGEN, P.L.M., HALABI, A. & DINGEMANSE, J. Single-and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole: 589
VAN GIERSBERGEN, P.L.M. *see* DINGEMANSE, J.
VAN GINNEKEN, E.E.M. *see* VERKAIK, N.J.
VAN GORP, E.C.M. *see* DE MAAT, M.M.R.
VAN HEESWIJK, R.P.G., COHEN STUART, J.W.T., BURGER, D.M., BEIJNEN, J.H., BORLEFFS, J.C.C. & HOETELMANS, R.M.W. Long-term suppression of viral replication despite low plasma saquinavir concentrations in the CHEESE Study: 211
VAN HOOFF, J.P. *see* STOLK, L.M.L.
VAN KASTEREN, M.E.F. *see* VOGTLÄNDER, N.P.J.
VAN KESTEREN, CH., MATHÔT, R.A.A., RAYMOND, E., ARMAND, J.P., DITTRICH, CH., DUMEZ, H., ROCHÉ, H., DROZ, J.P., PUNT, C., RAVIC, M., WANDERS, J., BEIJNEN, J.H., FUMOLEAU, P. & SCHELLENS, J.H.M. population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of the novel anticancer agent e7070 in four phase i studies, 553P
VAN KRAAIJ, D.J.W., HOVESTAD-WITTERLAND, A.H.I., DE METZ, M. & VOLLAARD, E.J. A comparison of the effects of nabumetone vs meloxicam on serum thromboxane B_2 and platelet function in healthy volunteers: 644
VAN PUIJENBROEK, E.P. *see* DE BRUIN, M.L.
VAN TELLINGEN, O. *see* VAN DEN BONGARD, H.J.G.D.
VARIOL, P. *see* NGUYEN, L.
VARLEY, P. *see* BRENNAN, N.
VERBOOM, L. *see* CROMHEECKE, H.
VERKAIK, N.J., VAN GINNEKEN, E.E.M., SMITS, P. & RONGEN, G.A. Adenosine-5′-triphosphate opens potassium channels in the forearm vascular bed: 545P
VERMEIJ, P. *see* CREMERS, S.
VERMEIJ, T.A.C. *see* KNOESTER, P.D.
VERSCHUREN, W.M.M. *see* MANTEL-TEEUWISSE, A.K.
VINVENT, J. *see* JOSEFSSON, M.
VISSER, L.E., GRAATSMA, H.H. & STRICKER, B.H.CH. Contraindicated NSAIDs are frequently prescribed to elderly patients with peptic ulcer disease: 183
VOGTLÄNDER, N.P.J., VAN KASTEREN, M.E.F., NATSCH, S., KULLBERG, B.J., HEKSTER, Y.A. & VAN DER MEER, J.W.M. Failure of prescribers to adjust antibiotic dose to impaired renal function in daily clinical practice: 557P
VOLLAARD, E.J. *see* VAN KRAAIJ, D.J.W.
VOSSEN, J. *see* CREMERS, S.

WAINER, I.W. *see* YASUDA, S.U.
WALTERS, M.R., BRADFORD, A.P.J., FISCHER, J. & LEES, K.R. Early clinical experience with the novel NMDA receptor antagonist CNS 5161., 305
WALTER-SACK, I. *see* MARTIN-FACKLAM, M.
WANDERS, J. *see* VAN KESTEREN, CH.
WANG, T. *see* RAZZAQUE, Z.
WARRINGTON, S. *see* BOYCE, M.
WATANABE, T. *see* TAGAWA, M.
WATSON, N. *see* SKRUMSAGER, B.K.
WEBB, D.J. *see* AFFOLTER, J.T.
WEBB, D.J. *see* COCKCROFT, J.R.
WEBB, D.J. *see* DE HAAS, S.L.
WEBB, D.J. *see* GODDARD, J.
WEBB, D.J. *see* LESLIE, S.J.
WEBB, D.J. *see* McENIERY, C.M.
WEBB, D.J. *see* OLIVER, J.J.
WEBB, D.J. *see* THOMSON, A.J.
WEBB, D.J. *see* WILKINSON, I.B.
WEBSTER, S., SANDERS, D.S., LOBO, A.J. & LENNARD, L. Azathioprine

metabolism in inflammatory bowel disease: Active metabolite concentrations and incidence of non-compliance: 440P
WELLER, C. *see* CHARLETT, A.
WEMER, JOHAN*see* TAMMINGA, WIM J.
WENZEL, R.R. *see* DAMMER, S.
WHITE, N.J. *see* SIMPSON, J.A.
WHITFIELD, K.M., MARRIOTT, J.F., WILSON, K.A. & RALSTON, C. Serum midazolam concentrations in critically ill paediatric cardiac surgery patients – a pilot study: 415P
WICKS, J. *see* BOYCE, M.
WILAIRATANA, P. *see* LOOAREESUWAN, S.
WILKINSON, I.B., HALL, I.R., TYRRELL, S., FRANKLIN, S.S. & COCKCROFT, J.R. Diastolic pressure predicts the risk of coronary heart disease in young adults: the role of pulse pressure amplification: 425P
WILKINSON, I.B., MACCALLUM, H., COCKCROFT, J.R. & WEBB, D.J. Inhibition of basal nitric oxide synthesis increases aortic augmentation index and pulse wave velocity *in vivo*: 189
WILKINSON, I.B. *see* AFFOLTER, J.T.
WILKINSON, I.B. *see* COCKCROFT, J.R.
WILKINSON, I.B. *see* DE HAAS, S.L.
WILKINSON, I.B. *see* McENIERY, C.M.
WILKINSON, I.B.W. *see* OLIVER, J.J.
WILLAVIZE, S. *see* JOSEFSSON, M.
WILLIAMS, D.P. *see* O'DONNELL, C.
WILLIAMS, D., BENNETT, K., HEEREY, A. & FEELY, J. Initial uptake and co-prescribing patterns of Buproprion (Zyban®): 431P
WILLIAMS, D., TELJEUR, C., BENNETT, K., KELLY, A. & FEELY, J. Influence of material deprivation on prescribing patterns within a deprived population: 431P
WILNER, K., LABOY, L. & LEBEL, M. The effects of cimetidine and antacid on the pharmacokinetic profile of sildenafil citrate in healthy male volunteers: 315
WILNER, K. *see* MUIRHEAD, G.J.
WILSON, K.A. *see* WHITFIELD, K.M.
WINDHORST, A.D. *see* FRANSSEN, E.J.F.
WOLF, D. *see* SCHUG, B.S.
WONG, F.A. *see* ABRAMS, L.S.
WONG, G. *see* NAISBITT, D.J.
WOOSLEY, R.L. *see* YASUDA, S.U.
WOUTERSE, A.C. *see* BISSLING, T.M.
WRIGHTON, S.A. *see* BELLE, D.J.
WULFF, M. *see* EARDLEY, I.
WULFFELÉ, M.G., KOOY, A., DE ZEEUW, D., STEHOUWER, C.D.A. & GANSEVOORT, R.T. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus; a systematic review: 549P
WYNNE, H. *see* KAMALI, F.

YANAI, K. *see* TAGAWA, M.
YANG, B.-H. *see* CHO, J.-Y.
YANG, C.-C., JICK, S.S. & JICK, H. Statins and the risk of idiopathic venous thromboembolism: 101
YANG, J.S., ROSTAMI-HODJEGAN, A. & TUCKER, G.T. Prediction of ritonavir interaction with sildenafil (Viagra): incorporating population variability: 438P
YASUDA, S.U., ZANNIKOS, P., YOUNG, A.E., FRIED, K.M., WAINER, I.W. & WOOSLEY, R.L. The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorpheniramine: 519
YEO, W.W. *see* ROWLAND YEO, K.
YIM, D.-S. *see* CHO, J.-Y.
YOSHIMOTO, H. *see* SAIMA, S.
YOUNG, A.E. *see* YASUDA, S.U.
YU, K.-S. *see* CHO, J.-Y.

ZANNIKOS, P. *see* YASUDA, S.U.

SUBJECT INDEX

This index was compiled from the keywords
(P = Proceedings, S = Supplement)

Absorption reduction, 312
ACE inhibition, 428P
ACE inhibitors, 37
Acetaminophen, 535
Acetylation, 155
Acetylsalicylic acid, 535
Activated charcoal, 312
Adenosine-5′-triphosphate, 545P
ADR classification, 318
Adsorption, 312
Adverse drug reactions, 207, 224, 318, 370
Age, 238
Albuterol, 555P, 556P
Alcohol, 421P
825T-allele, 422P
Allergic rhinitis, 107
Allergy, 250
Alosetron, 238
Amlodipine, 404, 405
Androgens, 469
Angiotensin converting enzyme inhibitors, 31
Angiotensin II, 193, 447P
Angiotensin II antagonism, 421P
Antacid, 31S
Antiatherogenic properties, 284
Antibiotics, 37S, 557P
Anticancer drug, 543P
Anticonvulsant hypersensitivity syndrome, 418P, 443P
Antidepressants, 111, 363
Anti-eotaxin-1 monoclonal antibody, 441P
Antihistamines, 250
Antihypertensive treatment, 31, 424P
Antinociception, 604
Antioxidant capacity, 446P
Antipsychotics, 551P
Aortic systolic blood pressure, 421P
Apolipoprotein E-genotypes, 548P
Arginine vasopressin, 429P
Arteether, 492
Artemether, 492
Artemotil, 492
Arterial stiffening, 421P
Arterial stiffness, 189, 428P
Artesunate, 23
Asthma, 3
Aspartic acid 301, 444P
Aspirin, 37
Asthma, 243, 416P
Ayahuasca, 613
Azathioprine, 440P, 546P
Azithromycin, 37S

β_2-adrenoceptor, 3
β-adrenoceptor blockers, 407
Benzodiazepines, 535
Bias, 370
Bioavailability, 1S, 5S, 347, 576, 582
Bioequivalence, 582
Bisphosphonates, 544P
Bisulphan, 386
Bladder dysfunction, 435P
Blood flow, 332
Blood pressure, 424P, 428P, 549P
Body weight, 337
Bone metabolism, 284
Book review: Antiviral agents: advances and problems, 542
Book review: Modern immunosuppressives, 216
Book review: Muscarinic receptors in airways diseases, 215
Book review: Neurotransmitters, drugs and brain function, 649
Book review: Recombinant protein drugs, 411
Book review: Review for Graduate Therapeutics, 215
Bosentan, 547P 589
Bradykinin, 37
Bupropion, 214, 431P

$C_{3435}T$ polymorphism, 420P
Caffeine, 155
Calcium channel antagonist, 203
Calcium channel blockers, 31, 243
Carbamazepine, 418P, 443P
Carboplatin, 83
Carboxylic acid, 446P
Cardiac arrhythmias, 370
Cardiac surgery, 415P
CAT-213, 441P
Cell trafficking, 474
Cellular growth, 447P
Cerebral metabolism, 275
Cetirizine, 250
CHEESE Study, 211
Chelating agents, 451
Chemotherapy, 439P
Children, 49, 207, 416P, 437P
Chlormethiazole, 275
Chloroquine, 404
Chlorpheniramine, 519
(+)-chlorpheniramine, 296
Chlorzoxazone, 155
Cholesterol, 549P
Chronic heart failure, 427P
Cimetidine, 31S
Cisplatin, 83
Clinical investigation, 642
Clinical pharmacology, 341
Clinical risk factors, 637
Clinical trials, 224
Clomiphene, 469
Clonidine,422P
Clotting tests, 147
Clozapine, 419P, 545P
Cognition, 296
Cointoxication, 535
Collagen 1 C-terminal telopeptide, 284
Compliance, 375, 440P
Confidence intervals, 407
Consistency of laser pain threshold, 43
Continuing medical education, 341
Continuing professional development, 341
Contraception, 141
Convulsions, 49
Coronary artery bypass grafting, 555P
Coronary circulation, 561
Coronary heart disease, 423P, 425P
Corticosteroids, 416P
COX isoenzymes, 255
COX-2 selectivity, 645
Creatinine, 398
Cremophor EL, 552P, 576
Cyclo-oxygenase inhibition, 645
CYP, 596
CYP2C19, 393
CYP2C19 genotypes, 550P
CYP2C9, 408
CYP2C9 polymorphisms, 409
CYP2D6, 111, 519
CYP2D6/2C19 null alleles, 550P
CYP3A, 67, 390
CYP3A4, 133, 203
CYP3A4 inhibitors, 45S
Cystatin C, 398
Cytochrome P450, 155
Cytochrome P450 2D6, 443P, 444P

Dapsone, 155
Deacetylation, 155
Debrisoquine, 111, 155
Delphi process, 341
Deprivation, 431P
Dextromethorphan, 604
Diabetes, 548P, 549P
Diastolic pressure, 425P
Diazepam, 49
Digoxin, 398
Dihydroartemisinin, 23
Diltiazem, 243
Disulfiram, 155
DMT, 613
DNA damage, 338
Dofetilide, 59
Doppler, 561
Dose-finding, 492
DPYD, 596
Drug abuse, 214
Drug interaction, 203, 508, 535, 558P
Drug misuse, 433P
Drug overdose, 214

© 2002 Blackwell Science Ltd

Drug utilization, 379
Duration of action, 61S

E7070, 553P
Ebastine, 296
Efavirenz, 212
Efficacy, 219, 418P
Egyptians, 596
Ejaculate, 53S
Elderly, 21S, 548P
Enantioselectivity, 255
Endothelial function, 413P
Endothelin antagonist, 355
Endothelin-1, 355
Endothelin$_A$ antagonism, 427P
Endothelin$_A$ receptor antagonism, 428P
Endothelin$_{A/B}$ antagonism, 427P
Endothelium, 193
Entacapone, 485
Enteric coated dosage form, 582
Enzyme induction, 203
Epilepsy, 123
Epirubicin, 508
Erectile dysfunction, 45S, 61S
Erythromycin, 37S, 133
Essential hypertension, 421P
Ethinyloestradiol, 67, 141
Etoposide, 83
European clinical trials directive, 416P
Evra^{TM}, 141
EXT-TEBCO^{R}, 430P

Falciparum malaria, 23
Fexofenadine, 526
Filtrass 2001, 426P
Flow cytometry, 75
Flumazenil, 554P
Food effect, 5S, 582
Forearm circulation, 429P
Formulation, 501

Gastric decontamination, 312
Gastric hyperacidity, 31S
Gastric lavage, 312
Gastric mucosa, 447P
Gastrin antagonist, 437P
Gender, 238, 418P, 474, 550P
Genotyping primers, 409
Glucose tolerance, 642
Glutamate, 642
Glutamate receptor, 305
Glutamic acid 216, 444P
Grapefruit juice, 405

Head injury, 275
Healthy postmenopausal women, 284
Healthy subjects, 589
Healthy volunteers, 582
Heart failure, 37
Helicobacter pylori, 163, 448P
Hepatic impairment, 21S
HIV-1 infection, 552P
HIV-positive patients, 212
HMG-CoA reductase inhibitor, 101, 548P
Hokanson EC4, 426P

Homeopathy, 433P
Hospital prescribing, 559P
Hospital prescribing errors, 326
5-HT$_{1B}$ receptors, 266
Human, 193
Human blood vessels, 266
Human milk, 17
Hypercholesterolaemia, 557P
Hypertension, 31, 93, 404
Hyponatraemia, 363

Idiopathic venous thromboembolism, 101
Incidence, 207, 379
Indirect response models, 474
Infant dose, 17
Infectious diseases, 559P
Inflammatory bowel disease, 440P, 546P
Informing study subjects, 436P
Infusion, 355
Insomnia, 196
Insulin, 469
Insulin secretion, 642
Insulin sensitivity, 642
Interaction, 83, 393, 403, 438P, 485, 555P
Intoxication, 312
Intramuscular injection, 23
Intranasal, 501
Intravascular ultrasound, 561
Intravenous, 501
Irradiation, 338

Kahalide F, 543P
Ketamine, 604
Ketoconazole, 589
Kidney function, 398

Large artery stiffness, 426P
Lead, 451
Lead paint, 451
Leukaemia, 439P
Levomeloxifene, 284
Lifestyle, 424P
Lignocaine, 133
Limited sampling strategy, 459
Lipid-lowering drug, 101, 379
5-lipoxygenase, 3
Lithium, 403
Liver failure, 536S
L-NMMA, 189, 193, 332

Malaria, 49, 492
Markers of coagulation activation, 147
Marketing surveillance, 224
MDR1, 526
MDR1 gene, 420P
Medication database, 558P
Medicine response test, 224
Mefloquine, 337
MEGX, 133
Melatonin, 543P
Menstruation, 469
Mephenytoin, 155
6-mercaptopurine, 546P
Metabolism, 508
Metformin, 469, 549P

Methadone, 212, 433P
Microalbuminuria, 31
Microdialysis, 275
Midazolam, 67, 133, 390, 415P, 437P, 501
Migrating motor complex, 582
Milk/plasma ratio, 17
Mizolastine, 250
Moclobemide, 393
Modelling, 501
Morphine, 347
Morphine-6-glucuronide, 347
Moxifloxacin, 232
Mucoadhesive solution, 107
Multiple dose trial, 285
Multiple drugs, 93

Nasal decongestant, 107
NCCOM3-R7, 430P
Neuroleptics, 111
Neuroprotection, 275, 305
Nevirapine, 552P
New antiepileptic drugs, 123
Nifedipine, 243, 582
Nilvadipine, 203
Nitrate tolerance, 414P
Nitric oxide, 189, 332, 426P, 428P, 429P
Nitroglycerin, 414P
NMDA-receptors, 604
Noise, 196
Non-linear mixed effect modeling, 552P
Nonsedating antihistamines, 370
Non-steroidal anti-inflammatory drugs, 645
Noradrenaline, 332
Norelgestromin, 141
Norgestrel, 67
Noxious heat, 604
NSAIDs, 173, 255, 446P, 535

Occupational exposure, 451
O-desmthylvenlafaxine, 17
Older people, 398
Olpadronate, 544P
Omeprazole, 545P
Onset of action, 61S
Opioid analgesics, 535
Oral anticoagulant therapy, 432P
Oral bioavailability, 390
Oral contraception, 637
Ortho Evra^{TM}, 141
Osmotic push-pull system, 582
Osteoarthritis, 629
Overdose, 416P
Ovulation, 469

Paclitaxel, 508
Paediatrics, 386, 433P
Paget's disease, 544P
Pantoprazole, 545P
Paracetamol, 312, 338, 446P, 535, 629
Paracetamol liquid *vs* tablet formulation, 43
Parkinson's disease, 551P
Parkinson's disease, 485
Parkinsonism, 448P
Patient counselling, 163
Patient preference, 435P

© 2002 Blackwell Science Ltd *Br J Clin Pharmacol*, **52**, 661–663

Patient self-reporting, 318
Patients' views
Peptic ulcer, 31S
Peptic ulcer disease, 163, 183
P-glycoprotein, 75, 420P, 526, 576
Pharmacodynamics, 1S, 59, 147, 34, 437P, 474, 485, 501, 508, 556P
Pharmaco-EEG, 613
Pharmacoepidemiology, 173
Pharmacoepidemiology, 326
Pharmacoepidemiology, 363
Pharmacogenetics, 3
Pharmacogenetics, 224, 596
Pharmacokinetic interactions, 547P, 147
Pharmacokinetics, 1S, 5S, 13S, 21S, 23, 31S, 37S, 49, 53S, 83, 133, 141, 212, 232, 238, 284, 337, 341, 347, 386, 437P, 440P, 441P, 485, 492, 501, 508, 519, 554P, 589
Pharmacovigilance, 370, 434P
Pharmacy records, 379
Phase 1 studies, 416P
Phenylalanine, 481, 483, 443P
Placenta, 548P
Plasma concentration, 296
Plasmodium falciparum, 492
Platelet function, 645
Plethysmography, 426P
Poisoning, 312, 535
Poisons information, 434P
Polycystic ovary syndrome, 469
Polymorphism, 3, 111, 408, 526
Population pharmacokinetics, 45S, 459, 543P, 552P, 553P
Population-based cohort study, 173
Positive turbo-ionspray tandem mass spectrometry, 543P
Potassium channels, 545P
Pulse wave tonometry, 414P
Predictors, 326
Prescribing information, 219
Prescribing patterns, 431P
Prescription database, 375
Preterm infant, 390
Prevalence, 379
Prick test, 250
Prospective study, 207
Prostaglandins, 193
Protein binding, 53S, 255
Psychedelics, 613
Psychiatric patients, 550P
Pulse pressure amplification, 425P
Pulse wave analysis, 189, 413

QT interval, 49
Quality of life, 432P

Race, 474
Rational prescribing, 559P
Rectal administration,23
Redox regulation, 419P
Relative benefit, 435P
Renal function, 557P
Renal impairment, 21S, 232
Residual effects, 196
Revalidation, 341
Review, 451
Rhodamine 123, 526
Rifampicin, 203
Risk, 423P
Risk factors, 424P
Ritonavir, 75, 438P
Rofecoxib, 403
RSD921, 440P

Safety, 5S, 13S, 21S, 31S, 37S, 53S, 219, 284
Saquinavir, 211, 576
Sedation, 437P
Selective oestrogen receptor modulator, 284
Selective serotonin reuptake inhibitors, 363
Serotonin, 407
Shear stress, 332
Sildenafil, 1S, 5S, 13S, 21S, 31S, 37S, 45S, 53S, 61S, 219, 438P
Simvastatin, 547P
Single dose trial, 284
Single nucleoside polymorphism, 224
Skin, 250
Sleep maintenance, 196
Sodium calcium edetate, 451
Sodium channel blocking agent, 440P
Sotalol, 555P
Sperm, 53S
Spontaneous reports, 370
St John's Wort, 75
Statins, 375, 423P
Stereoselectivity, 445P, 519
Stroke, 305
Substance P, 37
Succimer, 451
Suicide, 407
Sulfamethoxazole, 442P
Sustained release, 629
Syncope, 404
Systemic sclerosis, 414P

Tachistoscope, 296
Tachyphylaxis, 193
Tacrolimus, 554P
T-cells, 442P
Tezosentan, 355
Therapeutics, 341
6-thioguanine, 546P
Thiopurine methyltransferase, 439P
Thioridazine, 416P, 445P
Thoracic electrical bioimpedance monitors, 430P
Thrombin inhibitors, 147
Thromboxane B_2 synthesis, 645
Tolerability, 418P
Tolterodine, 418P
Topography, 613
TOXBASE®, 416P
Toxicity, 451
Transdermal glyceryl trinitrate, 414P
Triglycerides, 549P

UK national guidelines,
UK-103,320, 5S, 21S, 31S, 37S, 53S
UK-150,654, 13S
Upper GI bleeding, 173
Urotensin II, 428P

Vascular K_{ATP}-channels, 548P
Vasoconstriction, 266
Veins, 193
Venlafaxine, 17
Venous thromboembolism, 637
Vinorelbine, 459

Warfarin, 408
Warfarin, 485
Whole blood assay, 255

YF476, 437P
Young children, 415P

Zaleplon, 196
Zopiclone, 196